SGMO News and Press, Sangamo Therapeutics Inc. From 05/13/25

2025-05-13 04:36:16 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript Sangamo Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing...

2025-05-13 01:00:50 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript Sangamo Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing...

2025-05-12 21:06:52 ET Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Conference Call May 12, 2025, 06:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathali...

Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purc...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously pr...

Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

2025-05-11 17:35:00 ET More on Sangamo Therapeutics Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Present...

2025-05-11 08:00:29 ET Another busy week for corporate earnings is ahead, with a diverse range of companies set to report results, offering insights into various sectors ranging from e-commerce and technology to retail and industrials. Investors will be keenly watching the performance o...

Ironwood Pharmaceuticals Inc. (IRWD) is expected to report $-0.05 for Q1 2025 CaliberCos Inc. (CWD) is expected to report $-0.4 for Q1 2025 BlackRock TCP Capital Corp. (TCPC) is expected to report $0.34 for Q1 2025 INmune Bio Inc. (INMB) is expected to report $-0.43 for Q1 2025 No...